JPH11509844A5 - - Google Patents

Info

Publication number
JPH11509844A5
JPH11509844A5 JP1997506964A JP50696497A JPH11509844A5 JP H11509844 A5 JPH11509844 A5 JP H11509844A5 JP 1997506964 A JP1997506964 A JP 1997506964A JP 50696497 A JP50696497 A JP 50696497A JP H11509844 A5 JPH11509844 A5 JP H11509844A5
Authority
JP
Japan
Prior art keywords
nmda
sulfate
response
5β3βs
5β3αs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997506964A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11509844A (ja
JP4313435B2 (ja
Filing date
Publication date
Priority claimed from US08/559,442 external-priority patent/US5888996A/en
Application filed filed Critical
Priority claimed from PCT/US1996/012198 external-priority patent/WO1997003677A1/en
Publication of JPH11509844A publication Critical patent/JPH11509844A/ja
Publication of JPH11509844A5 publication Critical patent/JPH11509844A5/ja
Application granted granted Critical
Publication of JP4313435B2 publication Critical patent/JP4313435B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50696497A 1995-07-24 1996-07-24 プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 Expired - Fee Related JP4313435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US143995P 1995-07-24 1995-07-24
US60/001,439 1995-07-24
US50775795A 1995-07-26 1995-07-26
US08/507,757 1995-07-26
US08/559,442 US5888996A (en) 1995-07-26 1995-11-15 Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
US08/559,442 1995-11-15
PCT/US1996/012198 WO1997003677A1 (en) 1995-07-24 1996-07-24 Inhibition of nmda receptor activity by pregnenolone sulfate derivatives

Publications (3)

Publication Number Publication Date
JPH11509844A JPH11509844A (ja) 1999-08-31
JPH11509844A5 true JPH11509844A5 (https=) 2009-05-07
JP4313435B2 JP4313435B2 (ja) 2009-08-12

Family

ID=27356924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50696497A Expired - Fee Related JP4313435B2 (ja) 1995-07-24 1996-07-24 プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制

Country Status (4)

Country Link
US (1) US6083941A (https=)
EP (1) EP0840612A1 (https=)
JP (1) JP4313435B2 (https=)
WO (1) WO1997003677A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051599A1 (en) * 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
ATE360426T1 (de) 1998-11-10 2007-05-15 Curamentis Ltd Verwendung von agonisten der corticosteroidrezeptoren und einer suchtdroge zur suchtbehandlung
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
EP1212618B1 (en) * 1999-08-31 2009-03-11 Trustees Of Boston University Effect of steroids on nmda receptors depends on subunit composition
US20040204490A1 (en) * 1999-08-31 2004-10-14 Farb David H. Effect of steroids on NMDA receptors depends on subunit composition
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
AU2002217841A1 (en) * 2000-11-06 2002-05-15 Trustees Of Boston University Neuroactive steroid derivatives and methods of use
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
US7790404B2 (en) * 2001-08-20 2010-09-07 Sanford-Burnham Medical Research Institute Excitatory glycine receptors and methods
AUPR731901A0 (en) * 2001-08-28 2001-09-20 Goodchild, Colin Stanley Method of treatment
FR2850023B1 (fr) * 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
EP2301549A1 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
CN1906206A (zh) * 2004-01-15 2007-01-31 沃纳奇尔科特公司 雌二醇的二－甾族前体药物
CA2553816A1 (en) * 2004-01-15 2005-08-04 Warner Chilcott Company, Inc. Di-steroidal prodrugs of ethinyl estradiol
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1910401A2 (en) * 2005-07-12 2008-04-16 Warner Chilcott Company, Inc. 3-ester prodrugs of ethynylestradiol
CA2610481A1 (en) * 2005-07-12 2007-01-18 Warner Chilcott Company, Inc. 3-ester prodrugs of estradiol
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
JP4382735B2 (ja) * 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
WO2007049932A1 (en) * 2005-10-28 2007-05-03 Sun-Yeou Kim Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US20090203658A1 (en) * 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
WO2010077292A1 (en) * 2008-12-09 2010-07-08 King Faisal Specialist Hospital & Research Center Pregnenolone sulfate for the treatment of neurologic disorders
HRP20230747T1 (hr) * 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
FR2992645B1 (fr) * 2012-07-02 2014-08-01 Univ Claude Bernard Lyon Nouveaux derives de pyrrolidine
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CZ2014575A3 (cs) 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) * 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
EP3988096A1 (en) * 2020-10-26 2022-04-27 Universidad Pablo de Olavide OTRI Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep

Similar Documents

Publication Publication Date Title
US6083941A (en) Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives
JPH11509844A5 (https=)
US5888996A (en) Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
KR101546031B1 (ko) Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 치료적 접근법
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
JP2021507944A (ja) 運動ニューロン疾患を含む神経障害のための組成物および治療方法
AU2006229840B2 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2016134257A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
US8541395B2 (en) Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
Sadri‐Vakili et al. Inhibition of NMDA‐induced striatal dopamine release and behavioral activation by the neuroactive steroid 3α‐hydroxy‐5β‐pregnan‐20‐one hemisuccinate
US20110136769A1 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2024103012A1 (en) Polycyclic compounds for use in neurodegenerative conditions
EP1944041A1 (en) Therapeutic agent for neurogenic pain
JP2001513800A (ja) 医薬組成物調製のためのピバガビンの使用
CN116139140A (zh) 一种化合物在治疗糖皮质激素不良反应中的用途
Butler Effects of corticosterone and ethanol co-exposure on hippocampal toxicity: Potential role for the NMDA NR2B subunit